Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.

Front Immunol · 2021 · PMC8055954 · PMID 33889152

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, compared with the reference product, MSB11022 also showed a trend toward reduced incidence of serious TEAEs (9.7 vs. 4.9%, respectively) and treatment-related TEAEs (40 vs. 21.7%, respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.